Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003782406 | SCV004578054 | uncertain significance | Familial hypocalciuric hypercalcemia; Autosomal dominant hypocalcemia 1 | 2023-08-09 | criteria provided, single submitter | clinical testing | This variant, c.2747_2749dup, results in the insertion of 1 amino acid(s) of the CASR protein (p.Ser916dup), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CASR-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004366576 | SCV005035408 | uncertain significance | Nephrolithiasis/nephrocalcinosis | 2024-02-29 | criteria provided, single submitter | clinical testing | The c.2747_2749dupGCA variant (also known as p.S916dup), located in coding exon 6 of the CASR gene, results from an in-frame duplication of GCA at nucleotide positions 2747 to 2749. This results in the in-frame duplication of an extra serine residue at codon 916. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be neutral by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). In addition, the evidence for the gene-disease relationship is limited for pancreatitis and cancer predisposition; therefore, the clinical significance of this variant for CASR-related pancreatitis and cancer predisposition is unclear. Based on the available evidence, the clinical significance of this alteration remains unclear. |